



Prof. Kuo-Hsiang Chuang

Taipei Medical University, Taiwan



Short biography

Dr. Chuang is the CEO and founder of CytoArm Co., Ltd. He is also a professor at Taipei Medical University in Taiwan where he has worked for over 10 years. Dr. Chuang is a senior scientist with extensive experience in drug research and development, as well as international IP layout. He specializes in recombinant protein drug technology, tumor immunology, immune cell therapy, and autoimmune diseases.

Dr. Chuang has published over 50 SCI research papers, including several in top international journals such as *Biomaterials*, *Journal of Controlled Release*, and *Journal of Advanced Research* with an impact factor of over 10. Additionally, Dr. Chuang has applied for over 20 international invention patents and licensed two technologies to biotech companies.

In 2020, a team led by Dr. Chuang developed a new T cell technology platform known as Armed-T. This platform has been licensed exclusively to CytoArm Co., Ltd. The first Armed-T cell product is now available and will soon begin a phase I clinical trial to treat colorectal cancer in the United States, Singapore, and Taiwan.

Brief list of publications

1. Chen YJ, Chen M, Cheng TL, Tsai YS, Wang CH, Chen CY, Wu TY, Tzou SC, Wang KH, Cheng JJ, Kao AP, Lin SY*, **Chuang KH***. A Non-Genetic Engineering Platform for Rapidly Generating and Expanding Cancer-Specific Armed T Cells. *Journal of Biomedical Science* 2023 May 31;30(1):35. **IF= 11** [13/136 (9.6%) MEDICINE, RESEARCH & EXPERIMENTAL]
2. Wei PS, Chen YJ, Lin SY, **Chuang KH***, Sheu MT*, Ho HO*. In situ subcutaneously injectable thermosensitive PEG-PLGA diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 scFv T-cell/anti-EGFR Fab Engager (BiTEE). *Biomaterials* 2021 October 05;278:121166. **IF=14** [4/96 (4.2%) ENGINEERING, BIOMEDICAL]
3. Cheng WJ, **Chuang KH (equal 1st)**, Lo YJ, Chen M, Chen YJ, Roffler SR, Ho HO*, Lin SY*, Sheu MT* Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy. *Journal of Controlled Release* 2022 Apr;344:235-248. **IF= 10.8** [12/277 (4.3%) PHARMACOLOGY & PHARMACY]
4. Wu TY, Chen M, Chen IC, Chen YJ, Chen CY, Wang CH, Cheng JJ, Nepali K*, **Chuang KH***, Liou JP*. Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment. *Journal of Advanced Research*



NANO KOREA 2024

The 22nd International Nanotech Symposium & Exhibition

2022 Jun 22;S2090-1232(22)00148-5. **IF= 10.7** [10/73 (13.7%) MULTIDISCIPLINARY SCIENCES]

5. Cheng WJ, Lin SY, Chen M, Chen LC , Ho HO, **Chuang KH***, and Sheu MT*. Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity. ***International Journal of Nanomedicine*** 2021 June 10;16:4017-4030. **IF= 8.0** [18/277 (6.5%) PHARMACOLOGY & PHARMACY]